We attempted to investigate the relationship between GI cyclins and cyclin-dependent kinase inhibitors (CDKIs) while also taking into account earlier studies about the relationship between GI cyclins and human papillomavirus (HPV) status. Previously, we observed that cyclin D was downregulated in cases associated with HPV, while cyclin E played a leading role in neoplastic transformation. In this study, we analyzed the expression of CDKIs such as p21WAFI/CIPI, pI6INK4A, and p27KIP1 by means of immunohistochemistry in 22 cases of normal cervix, six cases of adenocarcinoma, 30 cases of cervical intraepithelial neoplasia (CIN), and 41 cases of squamous cell carcinoma (SCC). Stratum intermedium and parabasalis demonstrated strong intranuclear staining for all CDKIs. Reserve-cell hyperplasia and koilocytes revealed strong expression of CDKIs, whereas the neoplastic transformation in squamous lesions showed significantly decreased expression (ANOVA, p<.05). While normal endocervical cells revealed focal and weak expression to CDKIs, adenocarcinoma as well as glandular dysplasia revealed strong expression for all CDKIs but pI6INK4A. Both p16INK4A and cyclin D were negative in adenocarcinoma, and p16INK4A may be independent of cyclin D. There was strong correlation between cyclin E and p27KIP1, and cyclin E and p2 1wAFI/cIPl as well as among CDKIs. P16INK4A expression in case of SCC in cases associated with HPV type 16/18 was higher than in those lacking any type of HPV (t-test, p=.023). Downregulation of cyclin D in SCC associated with HPV seems to be inversely correlated with a relative overexpression of p16INK4A. On the other hand, p2lWAFI/CIPI and p27KIP1 demonstrated lower expressions in HPV-positive cases than in cases devoid of HPV, but they were not statistically significant. In conclusion, all CDKIs were downregulated in neoplastic transformation, with p1 6INK4A being relatively increased in SCC cases associated with HPV where cyclin D was kept inert. In addition, cyclin E could be activated in neoplastic transformation by eluding p2lWAFI/cIP1 and p27KIPI.
1. zur Hausen H, de Villiers EM. Human papilloma viruses. Ann Rev Microbiol48:427-447, 1994
2.
2. Herrington CS. Human papillomaviruses and cervical neoplasia. Interaction of hPV with other factors. J Clin Pathol48:1-6, 1995
3.
3. Pines J. Cyclins, CDKs and cancer. Semin Cancer Biol6:63-72, 1995
4.
4. Lukas J, Muller H, Bartkova J, et al. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin DI function in GI. J Cell Biol125:625-638, 1994
5.
5. Dulic V, Lees E, Reed SI. Association of human cyclin E with a periodic GI-S phase protein kinase. Science257:1958-1962, 1992
6.
6. Toyoshima H, Hunter T. p27, a novel inhibitor of GI cyclin-Cdk protein kinase activity, is related to p21. Cell78:67-74, 1994
7.
7. El-Deiry WS, Tokino T, Waldman T, Oliner JD, Velculescu VE, Burrell M, Hill DE, Healy E, Rees JL, Hamilton SR, Kinxler KW, Vogelstein B. Topological control of p2 1 wAFIcIPI expression in normal and neoplastic tissues. Cancer Res 55:2910-2919, 1995
8.
8. Yasui W, Akama Y, Kuniyasu H, Yokkoxaki H, Semba S, Shimamoto F, Tahara E. Expression of cyclin-dependent kinase inhibitor p2lWAFI/CIPI in nonneoplastic mucosa and neoplasia of the stomach: Relationship with p53 status and proliferative activity. J Pathol180:122-128, 1996
9.
9. Palazzo JP, Mercer E, Kovatich AJ, McHugh M. Immunohistochemical localization of p21WAFi CIP1 in normal, hyperplastic, and neoplastic uterine tissues. Hum Pathol27:60-66, 1997
10.
10. Serrano M, Hannnon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/Cdk4. Nature366:704-707, 1993
11.
11. Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y. Frequent somatic mutation of the MTS1/CDK4I gene in esophageal squamous cell carcinoma. Cancer Res54:3396-3397, 1994
12.
12. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hrubam RH, Yeo CJ, Kern SE. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocaricnoma. Nat Genet8:27-32, 1994
13.
13. Shapiro GJ, Edwards CD, Kobzik L, Godleski J, Richards W, Sugarbaker DJ, Rollins BJ. Reciprocal Rb inactivation and p161NK4 expression in primary lung cancers and cell lines. Cancer Res55:505-509, 1995
14.
14. Waga S, Hannnon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature369: 574-577, 1994
15.
15. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature366:701-704, 1993
16.
16. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell-Crowley L, Swindell W. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell6:387-400, 1995
17.
17. Hall M, Bates S, Peters G. Evidence for different models of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene11:1581-1588, 1995
18.
18. Polyak K, Lee MH, Erdhument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J. Cloning of p27KIP1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell78:59-66, 1994
19.
19. Cho NH, YT Kim, JW Kim. Correlation between GI cyclins and HPV in the uterine cervix. Int J Gynecol Pathol6:339-347, 1997
20.
20. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. Waf 1, a potential mediator of p53 tumor suppression. Cell75:817-825, 1993
21.
21. Pietenpol JA, Bohlander SK, Sato Y, Papadopoulos N, Liu B, Friedman C, Trask BJ, Roberts JM, Kinzler KW, Rowley JD, Vogelstein B. Assignment of the human p27KIP1 gene to 12p13 and its analysis in leukemias. Cancer Res55:1206-1210, 1995
22.
22. Ponce-Castaneda MV, Lee MH, Latres E, Polyak K, Lacombe L, Montgomery K, Mathew S, Krauter K, Sheinfeld J, Massague J, Cordon-Cardo C. p27KIP1: Chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res55:1211-1214, 1995
23.
23. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ. p57kip2, a structually distinct member of the p2 I cip 1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev9:650-662, 1995
24.
24. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ, Reed SI. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced GI arrest. Cell76:1013-1023, 1994
25.
25. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Kackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wilman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW, Vogelstein B. Wafl/Cipl is induced in p53-mediated GI arrest and apoptosis. Cancer Res54:1169-1174, 1994
26.
26. Lo KW, Huang DP, Lau KM. p16 gene alterations in nasopharyngeal carcinoma. Cancer Res55:2039-2043, 1995
27.
27. Kamb A, Gruis N, Feldhaus J, Liu Q, Harshnman K, Tavtigian S, Stockert E, Day R, Johnson B, Skolnick M. A cell cycle regulator potentially involved in genesis of many tumor types. Science264:436-439, 1994
28.
28. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature368:753-756, 1994
29.
29. Zhang SY, Klein-Szanto AJP, Sauter ER, Shafarenko M, Mitsunaga S, Nobori T, Carson DA, Ridge JA, Goodrow TL. Higher frequency of alterations in the p1 6/CDKN2 gene in squamous cell carcinomas cell lines than in primary tumors of the head and neck. Cancer Res54:5050-5053, 1994
30.
30. Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennett WP, Forrester K, Gerwin B, Serrano M, Beach DH, Harris CC. Mutations and altered expression of p161NK4 in human cancer. Proc Natl Acad Sci USA91:11045-11049, 1994
31.
31. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund J, Sidransky D. Rates of p16 (MTS 1) mutations in primary tumor with 9p loss. Science265:415-416, 1994
32.
32. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, Bartek J, Sidransky D. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res56:3630-3633, 1996
33.
33. Geradts J, Kratzke RA, Niehans GA, Lincoln CE. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2.MTS1) product p16 INK4 in archival human solid tumors: Correlation with retinoblastoma protein expression. Cancer Res55:6006-6011, 1995
34.
34. Vousden KH. Regulation of the cell cycle by viral oncoproteins. Sem Cancer Biol6:109-116, 1995
35.
35. Yeager T, Stadler W, Belair C, Puthenveettiil J, Olopade O, Reznikoff C. Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res55:493-497, 1995
36.
36. Sakaguchi M, Fujii Y, Hirabayashi H, Yoon H, Komoto Y, Oue T, Kusafuka T, Okada A, Matsuda H. Inverselt correlated expression of p16 and Rb protein in non-small cell lung cancers: An immunohistochemical study. Int J Cancer65:442-445, 1996
37.
37. Tam SW, Shay JW, Pagano M. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16 ink4. Cancer Res54:5816-5820, 1994
38.
38. Aagaard L, Lukas J, Bartkova J, Kjerutff AA, Straus M, Bartek J. Aberrations of p1 61NK4 and retinoblastoma tumor-suppresor genes occur in distinct subsets of human cancer cell lines. Int J Cancer61:115-120, 1995
39.
39. Nakao Y, Yang X, Yokoyama M, Ferenczy A, Tang S-C, Pater MM, Pater A. Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. Int J Cancer78:1410-1416, 1997
40.
40. Reznikoff CA, Yeager TR, Belair CD, Savelieva E, Puthenveettii JA, Stadler WM. Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. Cancer Res56:2886-2890, 1996
41.
41. Jung JM, Bruner JM, Ruan S, Langford LA, Kyritsis AP, Kobayashi T, Levin VA, Zhang W. Increased levels of p2lWAFI/CIPI in human brain tumors. Oncogene11:2021-2028, 1995
